Treatment of Chronic, Noninfectious, Nonnecrotizing Scleritis with Tumor Necrosis Factor Alpha Inhibitors

References

• Albini TA, Rao NA, Smith RE. The diagnosis and management of anterior scleritis. Int Ophthalmol Clin. 2005;45:191–204
   PubMedGoogle Scholar
• McCluskey PJ, Watson PG, Lightman S, et al. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 1999;106:2380–2386
   PubMed Web of Science ®Google Scholar
• Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130:469–476
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with rheumatoid arthritis and with other systemic immune-mediated diseases. Ophthalmology. 1994;101:1281–1288
   PubMed Web of Science ®Google Scholar
• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55:108–133
   PubMed Web of Science ®Google Scholar
• Hakin KN, Ham J, Lightman SL. Use of cyclosporin in the management of steroid dependent non-necrotising scleritis. Br J Ophthalmol. 1991;75:340–341
   PubMed Web of Science ®Google Scholar
• Reed MD, Chu DS. Immunomodulatory therapy for anterior segment ocular inflammation. Curr Opin Allergy Clin Immunol. 2002;2:429–433
   PubMedGoogle Scholar
• Lustig MJ, Cunningham ET. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol. 2003;14:399–412
   PubMedGoogle Scholar
• Gaudio PA. A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm. 2004;12:169–192
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492–513
   PubMed Web of Science ®Google Scholar
• Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol. 2005;50:351–363
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations from an expert panel. Am J Ophthalmol. 2000;130:492–513
   PubMed Web of Science ®Google Scholar
• Wakefield D, McCluskey P. Cyclosporin therapy for severe scleritis. Br J Ophthalmol. 1989;73:743–746
   PubMed Web of Science ®Google Scholar
• Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999;106:370–374
   PubMed Web of Science ®Google Scholar
• Sen HN, Suhler EB, Al-Khatib SQ, et al. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology. 2003;110:1750–1755
   PubMed Web of Science ®Google Scholar
• Kolomeyer AM, Ragam A, Shah K, et al. Mycophenolate mofetil in the treatment of non-infectious, non-necrotizing scleritis. Ocul Immunol Inflamm. 2012;20:113–118
   PubMed Web of Science ®Google Scholar
• Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992;99:1419–1423
   PubMed Web of Science ®Google Scholar
• Jachens AW, Chu DS. Retrospective review of methotrexate therapy in the treatment of chronic, non-infectious, non-necrotizing scleritis. Am J Ophthalmol. 2008;145:487–492
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440
   PubMed Web of Science ®Google Scholar
• Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 1998;10:397–422
   PubMed Web of Science ®Google Scholar
• Valesini G, Iannuccelli C, Marocchi E, et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev. 2007;7:35–41
   PubMed Web of Science ®Google Scholar
• Mease P. Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag. 2006;2:389–400
   PubMedGoogle Scholar
• Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2:137–147
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–986
   PubMed Web of Science ®Google Scholar
• Doctor P, Sultan A, Syed S, et al. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94:578–583
   Google Scholar
• Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125:895–900
   PubMed Web of Science ®Google Scholar
• Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory scleritis. Ophthalmology. 2004;111:352–356
   PubMed Web of Science ®Google Scholar
• Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252–257
   PubMed Web of Science ®Google Scholar
• Sen HN, Sangave A, Hammel K, et al. Infliximab for the treatment of active scleritis. Can J Ophthalmol. 2009;44:e9–e12
   PubMedGoogle Scholar
• Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol. 2010;29:559–561
   PubMed Web of Science ®Google Scholar
• Bawazeer AM, Raffa LH. Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis. Oman J Ophthalmol. 2011;4:139–141
   PubMedGoogle Scholar
• Sen HN, Sangaave AA, Goldstein DA, et al. A standardized grading system for scleritis. Ophthalmology. 2011;118:768–771
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol. 2005;140:509–516
   PubMed Web of Science ®Google Scholar
• Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease. Ocul Immunol Inflamm. 2012;20:198–202
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the Italian registry. J Rheumatol. 2013;40:74–79
   PubMed Web of Science ®Google Scholar
• Matsuda J, Kaburaki T, Kobayashi S, Numaga J. Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondlylitis. Jpn J Ophthalmol. 2013;57:104–107
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–598
   PubMed Web of Science ®Google Scholar
• Sugita S, Kawazoe Y, Imai A, et al. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Arthritis Res Ther. 2012;14:R99
   PubMed Web of Science ®Google Scholar
• Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20:18–26
   PubMed Web of Science ®Google Scholar
• Barrera P, van der Maas A, van Ede AE, et al. Drug survival, efficacy, and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology. 2002;41:430–439
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. doi:10.1038/nrgastro.2013.31. 2013-03-05
   Google Scholar